Fraction-dependent dose dynamics and clinical safety in high-risk neuroblastoma treated with [177Lu]Lu-DOTATATE: results from the LuDO-N trial
Se Whee Sammy Park, Fredrik Sundquist, Leonor Teles, Rob van Rooij, Daniel Thor, Kasper Karlsson, Arthur JAT Braat, Jakob Stenman, Joachim N Nilsson · 2026
Read Fraction-dependent dose dynamics and clinical safety in high-risk neuroblastoma treated with [177Lu]Lu-DOTATATE: results from the LuDO-N trial by Se Whee Sammy Park, Fredrik Sundquist, Leonor Teles, Rob van Rooij, Daniel Thor, Kasper Karlsson, Arthur JAT Braat, Jakob Stenman, Joachim N Nilsson (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13526122.txt.
Description
Se Whee Sammy Park and colleagues report, in a 2026 analysis of the LuDO-N trial, how absorbed radiation doses shifted between two treatment fractions in children and young patients with high-risk neuroblastoma. This tumor often displays somatostatin receptors, making it targetable by a radioactive drug, lutetium-177 DOTATATE. The trial intensified dosing across two fractions guided by dosimetry.
Fourteen patients with recurrent or refractory disease received a fixed first fraction, then a second adjusted to keep whole-body or kidney dose at target ceilings. Tumor-to-organ dose ratios fell by about forty-four percent at the second fraction, and tumors absorbed over half less dose per unit of activity, while organ doses fell less. Four patients needed stem cell rescue, and no lasting kidney toxicity appeared. The protocol now front-loads more activity into the first fraction.
Catalog record
| CREATOR | Se Whee Sammy Park, Fredrik Sundquist, Leonor Teles, Rob van Rooij, Daniel Thor, Kasper Karlsson, Arthur JAT Braat, Jakob Stenman, Joachim N Nilsson |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34223 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |